At the news
? NEUTRALIMPACT 3/10 8-K filed Nov 6, 2026 at 07:00 ET
Glaukos filed an 8-K to post a November 2026 investor presentation. The presentation reiterates the company's pipeline strategy across interventional glaucoma and keratoconus, highlights the iDose TR and Epioxa launches, and reaffirms revenue guidance of $1,000M for 2026/2027. No new material financial data or guidance changes were disclosed.
- Investor presentation dated November 2026 posted as Exhibit 99.1
- Revenue guidance midpoint of $1,000M for 2026/2027 as of the Q3 2026 earnings call on 10/28/2026
- Q3 2026 gross margin of 88%
- $340M cash and equivalents; no debt as of 9/30/2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access